Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has been selected to present at this year’s PCR London Valves conference, showcasing its life-changing DurAVR™ heart valve technology.
The conference is the largest international conference targeting heart professionals including interventional cardiologists, cardiothoracic surgeons and imaging specialists. It showcases the latest clinical trial data, novel technologies and clinical guidelines in heart valvular disease.
Anteris’ presentation is slated for the innovation sessions – this component of the conference is reserved for emerging technologies that are original, with clinically relevant/important data of interest to the medical community.
The company was chosen as one of only six presentations out of a total of 120 submissions made to this year’s conference.
“Year of recognition”
“We are honoured to have DurAVR™ accepted into the innovation session at this year’s PCR London Valves meeting, Anteris CEO Wayne Paterson said.
“This rounds out a year of recognition of this technology and the ADAPT premium anti calcification tissue with its real-world evidence at the highest levels of the global clinical and academic community.”
Anteris focuses on developing durable heart technology to help healthcare professionals deliver the best outcomes for their patients. The DurAVR™ aortic replacement valve uses next-generation scientific breakthroughs to address acute needs in patients, with its superior hemodynamic profile, as well as chronic, longer-term needs, with its sustained performance over the lifetime of the patient.
The patented technology has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.
The London presentation comes just weeks after AVR’s submission at this year’s Transcatheter Cardiovascular Therapeutics (TCT) conference in the US was accepted into the innovation session, further validating the clinical relevance of its technology.
Read: Anteris Technologies accepted into innovation session at prestigious Interventional cardiology meeting
– Susanna Nelson